|
|
|
| |
肿瘤新药(1995-2010) |
中国市场战略合作夥伴 药房网
|
|
|
| |
美国自1995到2010年上市的抗癌新药 |
|
| |
请点击药名本身进入订购,如果是多剂型,系统会将该药的各种剂型和价格直接列出。
Drugs
Approved in
2009
- Afinitor
(everolimus); Novartis; 肾癌新药, Approved March 2009
- Arzerra
(ofatumumab); GlaxoSmithKline;
治疗慢性淋巴细胞性白血病, Approved October 2009
- Avastin
(bevacizumab); Genentech; 肾癌新药, Approved July 2009
- Cervarix
[Human Papillomavirus Bivalent (Types 16 and 18) Vaccine,
Recombinant; GlaxoSmithKline; 预防由人乳头状瘤16-18病毒引起的宫颈癌和宫颈上皮细胞瘤, Approved October 2009
- Elitek
(rasburicase); sanofi-aventis;
用于控制恶性尿酸血症的血浆尿酸水平s,
Approved October 2009
- Folotyn
(pralatrexate injection); Allos Therapeutics;
治疗周围T-淋巴细胞淋巴瘤, Approved
September 2009
- Istodax
(romidepsin); Gloucester Pharmaceuticals; For the
treatment of 皮肤T-细胞淋巴瘤, Approved November
2009
- Onsolis
(fentanyl buccal); BioDelivery Sciences; 治疗癌痛, Approved July 2009
- Votrient
(pazopanib); GlaxoSmithKline; 治疗肾癌, Approved October of 2009
Drugs Approved in 2008
Drugs Approved in 2007
Drugs Approved in 2006
Drugs Approved in 2005
- Arranon (nelarabine) ; 治疗急性成淋巴细胞性白血病 T细胞淋巴瘤新药 GlaxoSmithKline生产; 2005年10 月批准上市。
- Nexavar
(sorafenib) ; 全球首个口服多激酶抑制剂,治疗晚期肾细胞癌的药物,Bayer/Onyx生产; 2005年12 月批准上市。
- Revlimid
(lenalidomide) ; 治疗轻中度-1-risk 骨髓增生异常综合征合; Celgene生产; 2005年12月批准上市。
- Abraxane ( PACLITAXEL PROTEIN-BOUND ) ; 美国制药伙伴公司(American Pharmaceutical
Partners,APP)和美国生物科学(American BioScience)近日宣布,美国FDA批准了Abraxane用于治疗转移性乳腺癌的新药申请。两家公司利用他们的专利纳米技术,把Abraxane的活性成分紫杉醇(Paclitaxel)和只有红细胞1%大小的纳米白蛋白颗粒结合在一起,从而避免了各种溶解可能。Abraxane是第一非溶解纳米白蛋白结合化疗药物,可以有效的利用白蛋白受体内在途径传输药物通过肿瘤新生血管内皮细胞壁。与单纯紫杉醇相比,其作用时间长,副作用小。
Drugs Approved in 2004
Drugs Approved in 2003
- Emend (aprepitant) ; 治疗化疗病人的恶心,呕吐; Merck生产; 2003年3月批准上市
- Iressa
(gefitinib) ; 治疗非小细胞肺癌的新药,AstraZeneca生产; 2003年5月批准上市
- Aloxi
(palonosetron) ; 预防肿瘤化疗病人的恶心,呕吐 ; MGI Pharma / Helsinn Healthcare研发生产; 2003年8月批准上市
- UroXatral (alfuzosin HCl extended-release tablets);治疗良性前列腺增生的各种症状; Sanofi-Synthelabo生产; 2003年6月批准上市
- Velcade (bortezomib) ; 治疗至少接受过二种以上疗法的多发性骨髓瘤得病人; Millennium Pharmaceuticals生产; 2003年5月批准上市
- exxar ; 治疗CD20阳性,的小囊性非霍杰金氏淋巴瘤化疗复发的病人; Corixa生产; 2003年6月批准上市
Drugs Approved in 2002
Drugs Approved in 2001
- Campath ; 注射用药治疗B-细胞慢性淋巴性白血病; 由Berlex Laboratories 开发生产 ; 2001年5月批准上市
- Femara (letrozole) 片剂; 停经后妇女罹患转移性乳癌的第一线治疗药物; 由Novartis 开发生产 ; 2001年1月批准上市
- Gleevec ; 治疗血癌 ( 慢性骨髓性白血病) chronic myelogenous leukemia
(CML) 非常有效,并对治疗胃肠基底细胞癌 (gastrointestinal stromal tumor) (GIST) 、前列腺癌等亦有明显效果 ; 由Novartis 开发生产 ; 2001年5月批准上市
- Kytril
(granisetron) Solution ; 化疗病人的恶心,呕吐; Hoffmann-La Roche生产; 2001年6月批准上市
- Trelstar LA ; 肌肉注射针剂,老年前列腺癌症治疗; Debiopharm
S.A.;生产; 2001年6月批准上市
- Xeloda ; 直肠结肠癌症口服化疗药; Hoffman-La Roche生产; 2001年5月批准上市
- Zometa
(zoledronic acid) ; 用于恶性高血钙症的治疗For the treatment of hypercalcemia of malignancy; Novartis生产; 2001年8月批准上市
Drugs Approved in 2000
Drugs Approved in 1999
- Aromasin Tablets; Exemestane Tablets, 25 mg; 乳癌患者改服 AROMASIN 更有可能保持癌症不复发 Pharmacia & Upjohn生产; 1999年10月批准上市
- Busulflex ; 合并用于白血病的综合治疗 ; Orphan Medical, Inc.生产; 1999年2月批准上市
- Doxil (doxorubicin HCl liposome injection); 治疗顽固性卵巢癌。适用于那些曾经用过当今一流的化疗方法医治过的顽固性卵巢癌患者。顽固性卵巢癌被定义为:在治疗过程中或完成治疗后6个月里病情不断恶化的疾病。Treatment for ovarian cancer that is refractory to other first-line therapies; Alza Corp.生产; 1999年6月批准上市;
- Ellence ; epirubicin hydrochloride; 可 治 疗 早 期 由 乳 癌 扩 散 至 淋 巴 结 癌 肿 的 女 性Pharmacia & Upjohn生产; 1999年9月批准上市;
- Ethyol (amifostine); 治疗肿瘤放疗病人的口腔干燥症(dry mouth); U.S. Bioscience and Alza Corp.生产; 1999年6月批准上市;
- Temodar ; 治疗难治性退行性星状细胞瘤; Schering-Plough生产; 1999年8月批准上市;
- UVADEX Sterile Solution; 治疗的皮肤T细胞淋巴瘤(Cutaneous T cell lymphoma,
CTCL)的皮肤改变; Therakos, Inc.生产; 1999年2月批准上市;
- Zofran ODT; 预防肿瘤化疗和放疗病人的恶心,呕吐; Glaxo Wellcome Inc.生产; 1999年1月批准上市;
Drugs Approved in 1998
- Actiq ; 治疗癌症疼痛 Pain; Anesta Corporation生产; 1998年11月批准上市;
- Anzemet ;治疗预防肿瘤化疗和手术病人的恶心,呕吐; 1998年2月批准上市
- Camptosar ; 治疗直肠结肠癌症; Pharmacia & Upjohn生产; 1998年10月批准上市
- Gemzar ; 治疗肺癌; Eli Lilly生产; 1998年8月批准上市
- Herceptin ; 治疗恶性乳房癌; Genentech生产; 1998年10月批准上市
- Neupogen ; 治疗肿瘤病人化疗后白细胞恢复缓慢; Amgen生产; 1998年4月批准上市
- Nolvadex ; 治疗乳腺癌; Zeneca Pharmaceuticals生产; 1998年10月批准上市
- Photofrin ; 治疗早期非小细胞肺癌 microinvasive endobronchial non-small cell lung cancer; QLT Therapeutics生产; 1998年1月批准上市
- Proleukin ; 治疗代谢性黑色素瘤 Chiron Corporation生产; 1998年1月批准上市
- Sclerosol Intrapleural Aerosol ; 治疗恶性胸腔积液; Bryan Corporation生产; 1998年1月批准上市
- Valstar ; 治疗膀胱癌; Anthra Pharmaceuticals生产; 1998年10月批准上市
- Xeloda ; 治疗进行性乳房癌瘤; Hoffmann LaRoche生产; 1998年4月批准上市
- Zofran ; 治疗成年人手术后的恶心,呕吐; Glaxo Wellcome生产; 1998年4月批准上市
Drugs Approved in 1997
- Anzemet ; Treatment for emesis; Hoechst Marion
Roussel; Approved September 1997
- Bromfenac ; Management of acute pain; Duract, Wyeth-Ayerst; Approved July 1997
- Femara ; Treatment for breast cancer; Novartis; Approved July 1997
- Gliadel Wafer (polifeprosan 20 with carmustine implant) ; Treatment for brain cancer; Rhone-Poulenc Rorer, Inc. and Guilford Pharmaceuticals Inc.; Approved February 1997
- Intron A ; Treatment for non-Hodgkin's lymphoma; Schering-Plough Corp.; Approved December 1997
- Kytril ; Prevention of nausea and vomiting associated with chemotherapy; SmithKline Beecham; Approved November 1997
- Lupron Depot ; Treatment for prostate cancer; Tap Holdings; Approved July 1997
- Miraluma test ; Test for breast cancer; DuPont Pharma Radiopharmaceuticals; Approved May 1997
- Neumega ; Treatment for thrombocytopenia; Genetics Institute; Approved November 1997
- Quadramet (Samarium Sm 153 Lexidronam Injection) ; Treatment for pain associated with bone cancer; DuPont Merck Pharmaceutical Company; Approved March 1997
- Rituxan ; Treatment for non-hodgkin's lymphoma; Idec Pharmaceuticals; Genentech Inc.; Approved November 1997
- Taxol ; Treatment for AIDS-related Kaposi's Sarcoma; Bristol-Myers Squibb; Approved August 1997
Drugs Approved in 1996
- Anexsia ; Treatment for chronic pain; Mallinckrodt Group; Approved August 1996
- Aredia (pamidronate disodium for injection) ; Treatment for osteolytic bone metastases of breast cancer; Chiron Therapeutics, Ciba Pharmaceuticals; Approved August 1996
- Arimidex (anastrozole) ; Treatment for advanced breast cancer in postmenopausal women; Zeneca; Approved January 1996
- Camptosar Injection ; Treatment for metastatic colorectal cancer; Pharmacia & Upjohn; Approved June 1996
- CEA-Scan; Diagnostic imaging product for colorectal cancer; Immunomedics; Approved April 1996
- Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) ; Treatment of meningeal leukemia or lymphocytic lymphoma; Orphan Medical, Inc.; Approved October 1996
- Eulexin (flutamide) ; Treatment for prostate cancer; Schering-Plough Corporation; Approved June 1996
- Feridex I.V. ; Contrast agent for magnetic resonance imaging of liver lesions; Advanced Magnetics; Approved February 1996
- GastroMARK ; Contrast agent for magnetic resonance imaging of the gastrointestinal tract; Advanced Magnetics; Approved May 1996
- Gemzar (Gemcitabine HCl) ; Treatment for pancreatic cancer; Eli Lilly; Approved May 1996
- Hycamtin (topotecan hydrochloride) ; Treatment for metastatic ovarian cancer; SmithKline Beecham; Approved May 1996
- Kadian ; Treatment for chronic moderate to severe pain; Purepac Pharmaceutical; Approved July 1996
- Leukine (sargramostim) ; Treatment for the replenishment of white blood cells; Immunex Corporation; Approved November 1996
- Lupron Depot (leuprolide acetate for depot suspension) ; Treatment for advanced prostate cancer; Abbott Laboratories; Approved January 1996
- Photodynamic Therapy; Photodynamic therapy device for the treatment of esophageal cancer; Sanofi Winthrop, QLT PhotoTherapeutics; Approved January, 1996
- Taxotere (Docetaxel) ; Treatment for locally advanced or metastatic breast cancer; Rhone Poulenc Rorer; Approved May 1996
- UltraJect ; Treatment for chronic pain; Mallinckrodt Group; Approved August 1996
- Visipaque (iodixanol) ; Diagnostic contrast agent; Nycomed; Approved April 1996
- Zoladex (10.8 mg goserelin acetate implant) ; Treatment for advanced prostate cancer; Zeneca; Approved January 1996
-
Drugs Approved in 1995
- Ethyol
(amifostine) ; Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer; Alza Pharmaceuticals, U.S. Bioscience; Approved December 8, 1995
- Intron A (Interferon alfa-2b, recombinant) ; An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma; Schering-Plough; Approved December 1995
- Leukine (sargramostim) ; Treatment for mobilizing peripheral blood progenitor cells for use after transplantation.; Immunex Corp.; Approved on November 24, 1995
- Self-examination breast pad; Self-examination breast pad; Inventive Products Inc.; Approved on December 22, 1995
|
|
| |
|
索取美国所有药品的英文说明书, 请登陆FDA网站 |
|
 |
|
|
查看美国肿瘤药品资料库 Drug
Information Summaries |
|
|
|
|